Ovarian Cancer Clinical Trial
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Summary
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Full Description
B9991046 is a master protocol that will consist of sub-studies from the following parent studies:
B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991
Eligibility Criteria
Inclusion Criteria:
Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
Participants must agree to follow the reproductive criteria.
Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
Exclusion Criteria:
Female participants who are pregnant or breastfeeding.
Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 58 Locations for this study
Fayetteville Arkansas, 72703, United States
Rogers Arkansas, 72758, United States
Springdale Arkansas, 72762, United States
Los Angeles California, 90024, United States
Los Angeles California, 90095, United States
Los Angeles California, 90095, United States
Tampa Florida, 33612, United States
Basking Ridge New Jersey, 07920, United States
Middletown New Jersey, 07748, United States
Montvale New Jersey, 07645, United States
Commack New York, 11725, United States
Harrison New York, 10604, United States
Long Island City New York, 11101, United States
New York New York, 10021, United States
New York New York, 10022, United States
New York New York, 10065, United States
Uniondale New York, 11553, United States
Philadelphia Pennsylvania, 19104, United States
Houston Texas, 77030, United States
Wollstonecraft New South Wales, 2060, Australia
Wollstonecraft New South Wales, 2065, Australia
Chermside Queensland, 4032, Australia
Chermside Queensland, 4032, Australia
Charleroi Hainaut, 6000, Belgium
Gent Oost-vlaanderen, 9000, Belgium
Edmonton Alberta, T6G 1, Canada
Kingston Ontario, K7L 2, Canada
Aalborg Nordjylland, 9000, Denmark
Vandoeuvre-lès-Nancy Lorraine, 54519, France
Budapest , 1122, Hungary
Milan Milano, 20133, Italy
Ancona , 60126, Italy
Roma , 00161, Italy
Chuo-ku Tokyo, 104-0, Japan
Koto Tokyo, 135-8, Japan
Fukuoka , 811-1, Japan
Yufu ÅŒita, 879-5, Japan
Namdong-gu Incheon-gwangyeoksi [incheon], 21565, Korea, Republic of
Goyang-si KyÇ’nggi-do, 10408, Korea, Republic of
Seongnam KyÇ’nggi-do, 13620, Korea, Republic of
Seoul Seoul-teukbyeolsi [seoul], 05505, Korea, Republic of
Seoul Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of
Seoul Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of
Auckland , 1023, New Zealand
Warszawa , 02-50, Poland
Warszawa , 02-78, Poland
Omsk Omskaya Oblast', 64401, Russian Federation
Pyatigorsk Stavropol'skiy KRAY, 35750, Russian Federation
Ufa , 45005, Russian Federation
Belgrade , 11000, Serbia
Barcelona Barcelona [barcelona], 08035, Spain
Barcelona Barcelona [barcelona], 08035, Spain
Barcelona Barcelona [barcelona], 08036, Spain
Hospitalet de Llobregat Barcelona, 08908, Spain
Barcelona , 08035, Spain
Madrid , 28040, Spain
Madrid , 28050, Spain
Sevilla , 41014, Spain
Tainan , 704, Taiwan
Taipei , 10002, Taiwan
Taoyuan , 333, Taiwan
London Kensington AND Chelsea, SW3 6, United Kingdom
Newcastle Upon Tyne , NE7 7, United Kingdom
Truro , TR1 3, United Kingdom
How clear is this clinincal trial information?